Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista de Saúde Pública |
Texto Completo: | https://www.revistas.usp.br/rsp/article/view/214471 |
Resumo: | OBJECTIVE: This work aims to analyze the quantity and expenses related to biological drugs used for the treatment of rheumatoid arthritis (RA) in outpatient public care within the Brazilian Unified Health System (SUS). METHODS: It is a cross-sectional descriptive study based on secondary data from a historical series, referring to the purchase, volume, and the number of patients treated with different biological drugs (infliximabe, etanercept, adalimumab, rituximab, abatacept, tocilizumab, golimumab, and certolizumab pegol) for RA treatment in outpatient care from 2012 to 2017. The data were extracted from the SUS Outpatient Information System database-SIA/SUS and included ten drugs used for RA treatment. The study assessed the quantity and expenditure of these drugs, the number of RA patients treated, and the expenditure by RA subtypes. The National Broad Consumer Price Index was used to adjust the expenditures for December 2017. RESULTS: Th e M inistry o f H ealth a llocated approximately $ 500 m illion t o provide a bout 2 million units of biological drugs for RA patients from 2012 to 2017. The supply of adalimumab 40 mg and etanercept 50 mg accounted for 68.3% of the total expenditure. The subtypes “other rheumatoid arthritis with rheumatoid factor” (ICD-10 M05.8), “rheumatoid arthritis without rheumatoid factor” (ICD-10 M06.0), and “Felty’s syndrome” (M05. 0) represented 84.5% of the total expenditures. The proportion of patients treated with biological drugs increased by 33.0%. There was a significant 83.0% increase in the number of patients using biological drugs compared to the overall number of RA patients treated during the study period. CONCLUSIONS: The results obtained allow us to draw a more recent profile of expenditure on RA treatment and indicate trends in the use of biological drugs for this condition, generating data that can support management decisions in public health policies. |
id |
USP-23_d9732cf9a8e07b82b5bb1b7e557941e9 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/214471 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health systemArthritis, RheumatoidDelivery of Health Care Public ExpendituresBiological ProductsPharmaceutical Services.OBJECTIVE: This work aims to analyze the quantity and expenses related to biological drugs used for the treatment of rheumatoid arthritis (RA) in outpatient public care within the Brazilian Unified Health System (SUS). METHODS: It is a cross-sectional descriptive study based on secondary data from a historical series, referring to the purchase, volume, and the number of patients treated with different biological drugs (infliximabe, etanercept, adalimumab, rituximab, abatacept, tocilizumab, golimumab, and certolizumab pegol) for RA treatment in outpatient care from 2012 to 2017. The data were extracted from the SUS Outpatient Information System database-SIA/SUS and included ten drugs used for RA treatment. The study assessed the quantity and expenditure of these drugs, the number of RA patients treated, and the expenditure by RA subtypes. The National Broad Consumer Price Index was used to adjust the expenditures for December 2017. RESULTS: Th e M inistry o f H ealth a llocated approximately $ 500 m illion t o provide a bout 2 million units of biological drugs for RA patients from 2012 to 2017. The supply of adalimumab 40 mg and etanercept 50 mg accounted for 68.3% of the total expenditure. The subtypes “other rheumatoid arthritis with rheumatoid factor” (ICD-10 M05.8), “rheumatoid arthritis without rheumatoid factor” (ICD-10 M06.0), and “Felty’s syndrome” (M05. 0) represented 84.5% of the total expenditures. The proportion of patients treated with biological drugs increased by 33.0%. There was a significant 83.0% increase in the number of patients using biological drugs compared to the overall number of RA patients treated during the study period. CONCLUSIONS: The results obtained allow us to draw a more recent profile of expenditure on RA treatment and indicate trends in the use of biological drugs for this condition, generating data that can support management decisions in public health policies.Universidade de São Paulo. Faculdade de Saúde Pública2023-07-19info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmlhttps://www.revistas.usp.br/rsp/article/view/21447110.11606/s1518-8787.2023057004280Revista de Saúde Pública; Vol. 57 No. 1 (2023); 41Revista de Saúde Pública; Vol. 57 Núm. 1 (2023); 41Revista de Saúde Pública; v. 57 n. 1 (2023); 411518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/rsp/article/view/214471/196673https://www.revistas.usp.br/rsp/article/view/214471/196672Copyright (c) 2023 Tacila Pires Mega, Rondineli Mendes da Silvahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMega, Tacila PiresSilva, Rondineli Mendes da2023-07-25T15:01:28Zoai:revistas.usp.br:article/214471Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2023-07-25T15:01:28Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
title |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
spellingShingle |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system Mega, Tacila Pires Arthritis, Rheumatoid Delivery of Health Care Public Expenditures Biological Products Pharmaceutical Services. |
title_short |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
title_full |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
title_fullStr |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
title_full_unstemmed |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
title_sort |
Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system |
author |
Mega, Tacila Pires |
author_facet |
Mega, Tacila Pires Silva, Rondineli Mendes da |
author_role |
author |
author2 |
Silva, Rondineli Mendes da |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Mega, Tacila Pires Silva, Rondineli Mendes da |
dc.subject.por.fl_str_mv |
Arthritis, Rheumatoid Delivery of Health Care Public Expenditures Biological Products Pharmaceutical Services. |
topic |
Arthritis, Rheumatoid Delivery of Health Care Public Expenditures Biological Products Pharmaceutical Services. |
description |
OBJECTIVE: This work aims to analyze the quantity and expenses related to biological drugs used for the treatment of rheumatoid arthritis (RA) in outpatient public care within the Brazilian Unified Health System (SUS). METHODS: It is a cross-sectional descriptive study based on secondary data from a historical series, referring to the purchase, volume, and the number of patients treated with different biological drugs (infliximabe, etanercept, adalimumab, rituximab, abatacept, tocilizumab, golimumab, and certolizumab pegol) for RA treatment in outpatient care from 2012 to 2017. The data were extracted from the SUS Outpatient Information System database-SIA/SUS and included ten drugs used for RA treatment. The study assessed the quantity and expenditure of these drugs, the number of RA patients treated, and the expenditure by RA subtypes. The National Broad Consumer Price Index was used to adjust the expenditures for December 2017. RESULTS: Th e M inistry o f H ealth a llocated approximately $ 500 m illion t o provide a bout 2 million units of biological drugs for RA patients from 2012 to 2017. The supply of adalimumab 40 mg and etanercept 50 mg accounted for 68.3% of the total expenditure. The subtypes “other rheumatoid arthritis with rheumatoid factor” (ICD-10 M05.8), “rheumatoid arthritis without rheumatoid factor” (ICD-10 M06.0), and “Felty’s syndrome” (M05. 0) represented 84.5% of the total expenditures. The proportion of patients treated with biological drugs increased by 33.0%. There was a significant 83.0% increase in the number of patients using biological drugs compared to the overall number of RA patients treated during the study period. CONCLUSIONS: The results obtained allow us to draw a more recent profile of expenditure on RA treatment and indicate trends in the use of biological drugs for this condition, generating data that can support management decisions in public health policies. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-07-19 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/214471 10.11606/s1518-8787.2023057004280 |
url |
https://www.revistas.usp.br/rsp/article/view/214471 |
identifier_str_mv |
10.11606/s1518-8787.2023057004280 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/214471/196673 https://www.revistas.usp.br/rsp/article/view/214471/196672 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Tacila Pires Mega, Rondineli Mendes da Silva https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Tacila Pires Mega, Rondineli Mendes da Silva https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/xml |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
dc.source.none.fl_str_mv |
Revista de Saúde Pública; Vol. 57 No. 1 (2023); 41 Revista de Saúde Pública; Vol. 57 Núm. 1 (2023); 41 Revista de Saúde Pública; v. 57 n. 1 (2023); 41 1518-8787 0034-8910 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1787713242691272704 |